<![CDATA[What the Health with Emily Casey]]>a7820050-24aa-58dc-8ba0-9a8e5ff30331Thu, 13 Aug 2026 22:44:52 +0000Captivate.fmDay One®https://artwork.captivate.fm/4674bbc7-da9b-4601-a917-2ac9028a8df5/what-the-health-the-day-one-network.jpgWhat the Health with Emily CaseyDay One®Day One®What The Health cuts through the BS in health innovation with honest conversations, rants, bants, practical insights, and the people shaping what's next. Less hype. More signal. Hosted by Emily Casey — Director of What The Health, one of Australia's leading health innovation media and communities of 11,000+, and Community & Partnership Lead at Tenmile. Brought to you with Tenmile (www.tenmile.com).https://dayone.fm/show/what-the-health-with-emily-casey/falseepisodicnopodcastHealthGPT and What Happens Now AI Is Table StakesHealthGPT and What Happens Now AI Is Table StakesA survey of more than 1,800 clinicians across 25 countries found 83% had already adopted AI before their workplace had any governance in place. Healthcare, it turns out, is not just adopting AI. It is being redesigned around it.

In the second What the Health Wrap, host Emily Casey is joined by Dr Simon Kos, Global Chief Medical Officer at Heidi, and Dr Janice Tan, GP and General Manager of Clinical Innovation at Bupa, to work through what the fortnight's biggest healthcare stories actually mean.

Simon uses Heidi's Pressure Points report to bust some long-held myths. Clinicians are not Luddites; get product-market fit right and they will adopt ahead of their own organisations. Product-led growth is not impossible in healthcare. And the idea that everything must run through a single electronic medical record screen does not survive contact with the reality of shadow AI. Janice agrees, arguing that GPs are among the most innovative professionals there are, and that what matters is not clicks or screens but the value exchange.

The conversation turns to where this leaves general practice. Both guests expect voice to become the default way information is entered within two years, freeing clinicians for deeper, more present consultations rather than merely shorter ones. Janice makes the point that scribes save time not to compress the visit but to enrich it. Simon argues that scribes should be commoditised, because they are the entry point to something bigger: infusing evidence and decision support into the flow of care.

They also examine what happens when patients bring their own AI into the room. OpenAI's launch of Health in ChatGPT, and the broader move by frontier labs into consumer health, could be the single biggest driver of health equity, filling the gap for people who previously had no care at all. But Simon draws a firm line between consumer-grade and clinical-grade health, pointing to the liability caps some providers attach to their advice and the accountability the medical profession is held to. The regulatory framework for quality and safety is not yet in place, but it is coming fast.

Janice explains Bupa's own metamorphosis from health insurer to health organisation, investing heavily in primary and preventive care across medical, dental, optical and psychology clinics, and rolling out AI scribes to its clinicians under strong governance. Simon zooms out to a health system whose old boundaries between payer, provider, acute, primary and consumer care are blurring, driven by digital capability, policy reform and a wave of consolidation.

The panel closes on the future of care. They discuss how to equip the next generation of doctors without letting AI become a crutch that erodes clinical judgement, what digital health's US$7.4 billion funding rebound says about capital concentrating into a handful of mega rounds, and why the companies winning big are the ones co-designing with clinicians from day one. Then they imagine the patient journey in 2035, from wellness chairs in autonomous vehicles to consultations that feel, as Janice puts it, more human.

Guests

Dr Simon Kos is Global Chief Medical Officer at Heidi, the AI clinical documentation company. A physician who practised critical care medicine before moving into digital health, he was previously Global Chief Medical Officer at Microsoft and CEO of Next Practice, and is a long-standing figure in Australian digital health.

Dr Janice Tan is a GP and the General Manager of Clinical Innovation at Bupa, where she leads the rollout and piloting of AI solutions across the group's health services. She also advises the RACGP and works to uplift the digital health capability of the GP profession.

Chapters

00:00 Introducing the What the Health Wrap

00:07 Guest updates: Heidi's global expansion and life in general practice

03:03 The fortnight's five biggest headlines

05:11 Heidi's Pressure Points report: adopting AI ahead of governance

06:16 Busting the myths about clinicians and technology

10:11 Where general practice is heading: voice by default and deeper consults

13:00 Patients are bringing their own AI to the consult

14:21 Health in ChatGPT and big tech's move into consumer health

18:33 Consumer-grade versus clinical-grade care and the regulation gap

23:41 Bupa's shift from health insurer to health company

30:29 Training the next generation without de-skilling

33:43 Digital health's US$7.4 billion funding landscape

35:31 Finding the wedge: co-designing with clinicians

38:46 The 2035 patient journey

42:46 Rapid fire: emojis, surprises and companies to watch

Links and resources


About the host

Emily Casey is the founder of What the Health and host of the What the Health Wrap, making major developments in health technology and innovation easier to understand.

The What the Health Wrap is brought to you by What the Health in partnership with Tenmile Ventures.

What the Health is part of Day One Network, the podcast and media network from W2D1 Media.

]]>A survey of more than 1,800 clinicians across 25 countries found 83% had already adopted AI before their workplace had any governance in place. Healthcare, it turns out, is not just adopting AI. It is being redesigned around it.

In the second What the Health Wrap, host Emily Casey is joined by Dr Simon Kos, Global Chief Medical Officer at Heidi, and Dr Janice Tan, GP and General Manager of Clinical Innovation at Bupa, to work through what the fortnight's biggest healthcare stories actually mean.

Simon uses Heidi's Pressure Points report to bust some long-held myths. Clinicians are not Luddites; get product-market fit right and they will adopt ahead of their own organisations. Product-led growth is not impossible in healthcare. And the idea that everything must run through a single electronic medical record screen does not survive contact with the reality of shadow AI. Janice agrees, arguing that GPs are among the most innovative professionals there are, and that what matters is not clicks or screens but the value exchange.

The conversation turns to where this leaves general practice. Both guests expect voice to become the default way information is entered within two years, freeing clinicians for deeper, more present consultations rather than merely shorter ones. Janice makes the point that scribes save time not to compress the visit but to enrich it. Simon argues that scribes should be commoditised, because they are the entry point to something bigger: infusing evidence and decision support into the flow of care.

They also examine what happens when patients bring their own AI into the room. OpenAI's launch of Health in ChatGPT, and the broader move by frontier labs into consumer health, could be the single biggest driver of health equity, filling the gap for people who previously had no care at all. But Simon draws a firm line between consumer-grade and clinical-grade health, pointing to the liability caps some providers attach to their advice and the accountability the medical profession is held to. The regulatory framework for quality and safety is not yet in place, but it is coming fast.

Janice explains Bupa's own metamorphosis from health insurer to health organisation, investing heavily in primary and preventive care across medical, dental, optical and psychology clinics, and rolling out AI scribes to its clinicians under strong governance. Simon zooms out to a health system whose old boundaries between payer, provider, acute, primary and consumer care are blurring, driven by digital capability, policy reform and a wave of consolidation.

The panel closes on the future of care. They discuss how to equip the next generation of doctors without letting AI become a crutch that erodes clinical judgement, what digital health's US$7.4 billion funding rebound says about capital concentrating into a handful of mega rounds, and why the companies winning big are the ones co-designing with clinicians from day one. Then they imagine the patient journey in 2035, from wellness chairs in autonomous vehicles to consultations that feel, as Janice puts it, more human.

Guests

Dr Simon Kos is Global Chief Medical Officer at Heidi, the AI clinical documentation company. A physician who practised critical care medicine before moving into digital health, he was previously Global Chief Medical Officer at Microsoft and CEO of Next Practice, and is a long-standing figure in Australian digital health.

Dr Janice Tan is a GP and the General Manager of Clinical Innovation at Bupa, where she leads the rollout and piloting of AI solutions across the group's health services. She also advises the RACGP and works to uplift the digital health capability of the GP profession.

Chapters

00:00 Introducing the What the Health Wrap

00:07 Guest updates: Heidi's global expansion and life in general practice

03:03 The fortnight's five biggest headlines

05:11 Heidi's Pressure Points report: adopting AI ahead of governance

06:16 Busting the myths about clinicians and technology

10:11 Where general practice is heading: voice by default and deeper consults

13:00 Patients are bringing their own AI to the consult

14:21 Health in ChatGPT and big tech's move into consumer health

18:33 Consumer-grade versus clinical-grade care and the regulation gap

23:41 Bupa's shift from health insurer to health company

30:29 Training the next generation without de-skilling

33:43 Digital health's US$7.4 billion funding landscape

35:31 Finding the wedge: co-designing with clinicians

38:46 The 2035 patient journey

42:46 Rapid fire: emojis, surprises and companies to watch

Links and resources


About the host

Emily Casey is the founder of What the Health and host of the What the Health Wrap, making major developments in health technology and innovation easier to understand.

The What the Health Wrap is brought to you by What the Health in partnership with Tenmile Ventures.

What the Health is part of Day One Network, the podcast and media network from W2D1 Media.

]]>c10506d3-c098-44ff-9579-eee73265dcf9Fri, 14 Aug 2026 06:00:00 +100055:17falsefull1221The A$2.2B Myricx Bio Deal, AI's Healthcare Land Grab and Preventive HealthThe A$2.2B Myricx Bio Deal, AI's Healthcare Land Grab and Preventive HealthNovartis has agreed to acquire Myricx Bio for up to US$1.5 billion, approximately A$2.2 billion, in a major outcome for a UK biotech company with deep Australian venture backing.

In the inaugural What the Health Wrap, host Emily Casey is joined by Dr Jackie Rabec, co-founder and Chief Product Officer at ThinkMD.ai, and Dr Prashanth Rajan, Associate at Brandon Capital, to work through what the fortnight's biggest healthcare stories actually mean.

Prashanth explains how Myricx Bio evolved from small-molecule science into a new class of antibody-drug conjugate payloads. He discusses why the proposed acquisition matters for cancer therapeutics, investors and Australia's biotech ecosystem, while cautioning that the ultimate test will still come through clinical development.

The conversation then turns to artificial intelligence. Jackie argues that healthcare companies need more than a powerful model. They need a genuine problem, sustainable economics, clinical workflow integration and the change management required for adoption. Prashanth applies the same test to AI drug discovery, where molecular designs must still survive laboratory testing and clinical trials.

The panel also examines proposed changes to Australia's R&D Tax Incentive. Under the current proposal, the offset would be refundable for eligible businesses younger than ten years and non-refundable for older businesses. Prashanth explains why that distinction could affect biotech companies just as expensive clinical programs begin to scale, potentially pushing investment, clinical activity and company growth offshore.

AdvanCell's US$315 million Series D offers a timely example of what sustained local support can produce. The company is advancing a Lead-212 targeted alpha therapy for metastatic prostate cancer while expanding its isotope supply and manufacturing infrastructure.

Finally, the panel asks whether preventive health and longevity represent the future of care or another layer available mainly to people who can afford it. Everlab's A$65 million Series A and Neko Health's US$700 million Series C demonstrate growing demand, but questions remain about equity and whether earlier intervention can reduce pressure on public healthcare systems.

Guests

Dr Jackie Rabec is co-founder and Chief Product Officer at ThinkMD.ai, which builds offline-capable clinical decision-support tools for frontline health workers. She previously worked at Google and was Head of Product at Heidi Health.

Dr Prashanth Rajan is an Associate at Brandon Capital and leads its activities in New South Wales. He has a background in bioinformatics, biochemistry and molecular biology.

Chapters

00:00 Introducing the What the Health Wrap

08:07 Myricx Bio's proposed US$1.5 billion acquisition

11:13 Antibody-drug conjugates and Australian biotech

15:35 AI in healthcare beyond administration

24:50 The promise and limits of AI drug discovery

28:46 Proposed changes to Australia's R&D Tax Incentive

35:22 AdvanCell's US$315 million Series D

42:25 Preventive health, longevity and primary care

53:28 Rapid fire: platform risk, companies to watch and useful resources

Links and resources

ThinkMD.ai: https://www.thinkmd.ai/

Dr Prashanth Rajan at Brandon Capital: https://brandoncapital.vc/team_member/prashanth-rajan/

Myricx Bio acquisition announcement: https://brandoncapital.vc/2026/07/06/brandon-capital-announces-agreement-for-novartis-to-acquire-portfolio-company-myricx-bio-to-advance-new-class-of-cancer-therapeutics/

Australian Treasury's R&D Tax Incentive proposal: https://treasury.gov.au/sites/default/files/2026-06/p2026-781365_0.pdf

Claude for Healthcare: https://www.anthropic.com/news/healthcare-life-sciences

Chai Discovery's US$400 million Series C: https://www.chaidiscovery.com/news/series-c

AdvanCell's US$315 million Series D: https://svhealthinvestors.com/news/advancell-closes-us-315-million-oversubscribed-series-d-financing-to-advance-targeted-alpha-therapies-and-expand-clinical-and-commercial-manufacturing-infrastructure

Everlab: https://www.everlab.com.au/

Neko Health's US$700 million Series C: https://www.nekohealth.com/se/en/press/neko-health-raises-usd700m-series-c-ahead-of-us-launch

About the host

Emily Casey is the founder of What the Health and host of the What the Health Wrap, making major developments in health technology and innovation easier to understand.

The What the Health Wrap is brought to you by What the Health in partnership with Tenmile Ventures.

What the Health is part of Day One Network, the podcast and media network from W2D1 Media: https://dayone.fm/

]]>Novartis has agreed to acquire Myricx Bio for up to US$1.5 billion, approximately A$2.2 billion, in a major outcome for a UK biotech company with deep Australian venture backing.

In the inaugural What the Health Wrap, host Emily Casey is joined by Dr Jackie Rabec, co-founder and Chief Product Officer at ThinkMD.ai, and Dr Prashanth Rajan, Associate at Brandon Capital, to work through what the fortnight's biggest healthcare stories actually mean.

Prashanth explains how Myricx Bio evolved from small-molecule science into a new class of antibody-drug conjugate payloads. He discusses why the proposed acquisition matters for cancer therapeutics, investors and Australia's biotech ecosystem, while cautioning that the ultimate test will still come through clinical development.

The conversation then turns to artificial intelligence. Jackie argues that healthcare companies need more than a powerful model. They need a genuine problem, sustainable economics, clinical workflow integration and the change management required for adoption. Prashanth applies the same test to AI drug discovery, where molecular designs must still survive laboratory testing and clinical trials.

The panel also examines proposed changes to Australia's R&D Tax Incentive. Under the current proposal, the offset would be refundable for eligible businesses younger than ten years and non-refundable for older businesses. Prashanth explains why that distinction could affect biotech companies just as expensive clinical programs begin to scale, potentially pushing investment, clinical activity and company growth offshore.

AdvanCell's US$315 million Series D offers a timely example of what sustained local support can produce. The company is advancing a Lead-212 targeted alpha therapy for metastatic prostate cancer while expanding its isotope supply and manufacturing infrastructure.

Finally, the panel asks whether preventive health and longevity represent the future of care or another layer available mainly to people who can afford it. Everlab's A$65 million Series A and Neko Health's US$700 million Series C demonstrate growing demand, but questions remain about equity and whether earlier intervention can reduce pressure on public healthcare systems.

Guests

Dr Jackie Rabec is co-founder and Chief Product Officer at ThinkMD.ai, which builds offline-capable clinical decision-support tools for frontline health workers. She previously worked at Google and was Head of Product at Heidi Health.

Dr Prashanth Rajan is an Associate at Brandon Capital and leads its activities in New South Wales. He has a background in bioinformatics, biochemistry and molecular biology.

Chapters

00:00 Introducing the What the Health Wrap

08:07 Myricx Bio's proposed US$1.5 billion acquisition

11:13 Antibody-drug conjugates and Australian biotech

15:35 AI in healthcare beyond administration

24:50 The promise and limits of AI drug discovery

28:46 Proposed changes to Australia's R&D Tax Incentive

35:22 AdvanCell's US$315 million Series D

42:25 Preventive health, longevity and primary care

53:28 Rapid fire: platform risk, companies to watch and useful resources

Links and resources

ThinkMD.ai: https://www.thinkmd.ai/

Dr Prashanth Rajan at Brandon Capital: https://brandoncapital.vc/team_member/prashanth-rajan/

Myricx Bio acquisition announcement: https://brandoncapital.vc/2026/07/06/brandon-capital-announces-agreement-for-novartis-to-acquire-portfolio-company-myricx-bio-to-advance-new-class-of-cancer-therapeutics/

Australian Treasury's R&D Tax Incentive proposal: https://treasury.gov.au/sites/default/files/2026-06/p2026-781365_0.pdf

Claude for Healthcare: https://www.anthropic.com/news/healthcare-life-sciences

Chai Discovery's US$400 million Series C: https://www.chaidiscovery.com/news/series-c

AdvanCell's US$315 million Series D: https://svhealthinvestors.com/news/advancell-closes-us-315-million-oversubscribed-series-d-financing-to-advance-targeted-alpha-therapies-and-expand-clinical-and-commercial-manufacturing-infrastructure

Everlab: https://www.everlab.com.au/

Neko Health's US$700 million Series C: https://www.nekohealth.com/se/en/press/neko-health-raises-usd700m-series-c-ahead-of-us-launch

About the host

Emily Casey is the founder of What the Health and host of the What the Health Wrap, making major developments in health technology and innovation easier to understand.

The What the Health Wrap is brought to you by What the Health in partnership with Tenmile Ventures.

What the Health is part of Day One Network, the podcast and media network from W2D1 Media: https://dayone.fm/

]]>c04d849e-929e-4f2e-8f80-ed4d8a6e76c3Mon, 27 Jul 2026 06:00:00 +100059:34falsefull1111